Close

Takeda (TAK) Enters Pact with Ovid Therapeutics (OVID) for Rights to Develop and Commercialize Soticlestat for Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. TSLA
2. ENPH
3. TXN
4. SPOT
5. META
6. BA
7. V
8. IBM
9. KMB
10. HCP


Go back to Takeda (TAK) Enters Pact with Ovid Therapeutics (OVID) for Rights to Develop and Commercialize Soticlestat for Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
(NASDAQ: OVID) Delayed: 3.15 -0.05 (1.56%)
Previous Close $3.20    52 Week High $ 
Open $3.18    52 Week Low $ 
Day High $3.22    P/E N/A 
Day Low $3.11    EPS $ 
Volume 113,127       

(NYSE: TAK) Delayed: 13.23 -0.15 (1.12%)
Previous Close $13.38    52 Week High $0.55 
Open $13.32    52 Week Low $0.55 
Day High $13.33    P/E N/A 
Day Low $13.21    EPS $-0.20 
Volume 924,525